CO44668 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)

NCT05904886

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152) (SKYSCRAPER-14)

Associated Conditions

Liver Cancer

Principal Investigator

Sponsor

Hoffmann-La Roche

The purpose of this study is to compare the effects, good or bad, of tiragolumab plus atezolizumab plus bevacizumab versus placebo plus atezolizumab plus bevacizumab on patients with HCC. In this study, you will get either tiragolumab plus atezolizumab plus bevacizumab or placebo plus atezolizumab plus bevacizumab. A placebo looks like a drug but has no active ingredient.
About 650 people will take part in this study. Tiragolumab is an experimental drug, which means health authorities, such as the FDA, have not approved tiragolumab in combination with atezolizumab and bevacizumab for the treatment of HCC.

This study is currently enrolling.